PURPOSE: Mass drug administration (MDA) is part of the SAFE strategy for trachoma elimination. This study examined the effect of three annual MDAs on prevalence of trachoma among 13 longitudinal cohorts of Tanzanian children. METHODS:Children younger than 10 years were assigned to cohorts based on age at baseline and followed annually for 3 years, with newborns assigned to new cohorts over time. Annual MDA consisted of topical tetracycline for children younger than 6 months and oralazithromycin for those 6 months and older. Follicular trachoma (TF) and Chlamydia trachomatis infection status were assessed annually before the next MDA. Prevalence and risk factors for TF and infection at each age were compared across cohorts. RESULTS: At each survey, most age groups and cohorts had MDA coverage of more than 80% and showed decreased TF prevalence after every MDA. One cohort had consistently lower coverage, higher-than-expected TF and infection at ages 6 and 7, and elevated risk of TF at age 7 relative to the preceding cohort in spite of receiving one additional MDA (odds ratio 2.3, 95% confidence interval 1.0-5.2). Cohorts aged 1 or older at baseline generally showed reductions in TF and infection after each MDA, whereas younger cohorts showed decreased infection but increased TF over time. Successive cohorts of never-treated children younger than 1 year showed sequential TF and infection reductions with each MDA (P < 0.001). CONCLUSIONS: Multiple MDAs significantly reduce trachoma prevalence and appear to increasingly protect children born into these communities. The youngest children show declining/stable rates of infection but increasing rates of trachoma, which may reflect longer duration of clinical signs.
RCT Entities:
PURPOSE: Mass drug administration (MDA) is part of the SAFE strategy for trachoma elimination. This study examined the effect of three annual MDAs on prevalence of trachoma among 13 longitudinal cohorts of Tanzanian children. METHODS:Children younger than 10 years were assigned to cohorts based on age at baseline and followed annually for 3 years, with newborns assigned to new cohorts over time. Annual MDA consisted of topical tetracycline for children younger than 6 months and oral azithromycin for those 6 months and older. Follicular trachoma (TF) and Chlamydia trachomatis infection status were assessed annually before the next MDA. Prevalence and risk factors for TF and infection at each age were compared across cohorts. RESULTS: At each survey, most age groups and cohorts had MDA coverage of more than 80% and showed decreased TF prevalence after every MDA. One cohort had consistently lower coverage, higher-than-expected TF and infection at ages 6 and 7, and elevated risk of TF at age 7 relative to the preceding cohort in spite of receiving one additional MDA (odds ratio 2.3, 95% confidence interval 1.0-5.2). Cohorts aged 1 or older at baseline generally showed reductions in TF and infection after each MDA, whereas younger cohorts showed decreased infection but increased TF over time. Successive cohorts of never-treated children younger than 1 year showed sequential TF and infection reductions with each MDA (P < 0.001). CONCLUSIONS: Multiple MDAs significantly reduce trachoma prevalence and appear to increasingly protect children born into these communities. The youngest children show declining/stable rates of infection but increasing rates of trachoma, which may reflect longer duration of clinical signs.
Entities:
Keywords:
Tanzania; cohort study; mass drug administration (MDA); population-based study; trachoma
Authors: Dianne Stare; Emma Harding-Esch; Beatriz Munoz; Robin Bailey; David Mabey; Martin Holland; Charlotte Gaydos; Sheila West Journal: Ophthalmic Epidemiol Date: 2011-02 Impact factor: 1.648
Authors: Jenafir I House; Berhan Ayele; Travis C Porco; Zhaoxia Zhou; Kevin C Hong; Teshome Gebre; Kathryn J Ray; Jeremy D Keenan; Nicole E Stoller; John P Whitcher; Bruce D Gaynor; Paul M Emerson; Thomas M Lietman Journal: Lancet Date: 2009-03-28 Impact factor: 79.321
Authors: Paul M Emerson; Matthew Burton; Anthony W Solomon; Robin Bailey; David Mabey Journal: Bull World Health Organ Date: 2006-08 Impact factor: 9.408
Authors: Luis Carlos Cajas-Monson; Harran Mkocha; Beatriz Muñoz; Thomas C Quinn; Charlotte A Gaydos; Sheila K West Journal: PLoS Negl Trop Dis Date: 2011-03-15
Authors: Daniel P Morberg; Wondu Alemayehu; Muluken Melese; Takele Lakew; Alemayehu Sisay; Zhaoxia Zhou; Vicky Cevallos; Catherine E Oldenburg; Travis C Porco; Thomas M Lietman; Jeremy D Keenan Journal: Ophthalmic Epidemiol Date: 2018-08-28 Impact factor: 1.648
Authors: Stephanie J Migchelsen; Diana L Martin; Khamphoua Southisombath; Patrick Turyaguma; Anne Heggen; Peter Paul Rubangakene; Hassan Joof; Pateh Makalo; Gretchen Cooley; Sarah Gwyn; Anthony W Solomon; Martin J Holland; Paul Courtright; Rebecca Willis; Neal D E Alexander; David C W Mabey; Chrissy H Roberts Journal: PLoS Negl Trop Dis Date: 2017-01-18
Authors: Athumani M Ramadhani; Tamsyn Derrick; David Macleod; Patrick Massae; Elias Mafuru; Aiweda Malisa; Kelvin Mbuya; Chrissy H Roberts; William Makupa; Tara Mtuy; Robin L Bailey; David C W Mabey; Martin J Holland; Matthew J Burton Journal: PLoS Negl Trop Dis Date: 2019-08-14
Authors: Jade Benjamin-Chung; Jaynal Abedin; David Berger; Ashley Clark; Veronica Jimenez; Eugene Konagaya; Diana Tran; Benjamin F Arnold; Alan E Hubbard; Stephen P Luby; Edward Miguel; John M Colford Journal: Int J Epidemiol Date: 2017-08-01 Impact factor: 9.685